Q4 2026 Gufic Biosciences Ltd Earnings Call Transcript
Key Points
- Gufic Biosciences Ltd (BOM:509079) achieved its strongest quarter ever in Q4 FY26 with revenue of INR252 crores and an EBITDA margin increase to 17.7%.
- The company successfully reached 30% capacity utilization at its Indore facility, achieving EBITDA breakeven.
- International business saw significant growth, with new product approvals in multiple countries and a partnership with a major global health organization.
- The domestic women's health platform delivered its strongest year ever, with notable achievements in the fertility and gynecology segments.
- Gufic signed an in-licensing agreement with a leading Canadian aesthetics company, enhancing its aesthetic portfolio with a credible filler offering.
- The company experienced a revenue impact of INR22 crores due to a working capital reset in the Critical Care cluster.
- Despite revenue growth, the overall profit after tax for FY26 decreased compared to the previous year.
- The transition to a new international business model incurred additional costs, impacting short-term profitability.
- The company faces challenges in maintaining margins due to potential price erosion in the critical care segment.
- Debt levels remain high at INR400 crores, with expectations to maintain this level due to working capital needs.
Ladies and gentlemen, good day, and welcome to Gufic Biosciences Limited Q4 and FY26 earnings conference call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Ms. Ami Shah, Company Secretary, Gufic Biosciences Limited. Thank you, and over to you, ma'am.
Thank you, Yousuf. Good afternoon, everyone, and I thank you all for joining us today to discuss Gufic Biosciences Limited's financial results for the fourth quarter and full year ended FY26. The press release and investor presentation relating to today's results have been submitted to the stock exchanges and are also available on our website for your reference. Let me now begin with introducing the management team who has joined today's call.
We have with us Mr. Pranav Choksi, CEO and Director; Mr. Devkinandan Roonghta, CFO; and Mr. Avik Das from the Investor Relations team. We will now commence the session with the opening remarks from Avik, following which we will open
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
